51 active not recruiting. 51 Phase 2, 5 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 51 | Active not recruiting 51 |
| Phase 1 | 5 | Active not recruiting 5 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Advanced Malignant Solid Neoplasm: new trials by email Literature Review of Advanced Malignant Solid Neoplasm trials Research Report on Advanced Malignant Solid Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial) Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 105 | 2024-08-01 | 2026-10-22 |
| Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 88 | 2022-11-14 | 2026-09-25 |
| Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 54 | 2020-07-17 | 2026-10-27 |
| Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 54 | 2019-12-14 | 2026-11-02 |
| Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K) Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 35 | 2019-08-08 | 2026-06-01 |
| Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L) Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 35 | 2019-07-24 | 2026-10-15 |
| Open Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 2 / Phase 3 | Active not recruiting | M.D. Anderson Cancer Center | 100 | 2019-03-30 | 2026-08-11 |
| Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy Atezolizumab, Niraparib, Quality-of-Life Assessment - Advanced Malignant Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Jonsson Comprehensive Cancer Center | 59 | 2019-03-06 | 2026-02-12 |
| Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Malignant Solid Neoplasm, Glioblastoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 89 | 2019-01-30 | 2026-09-09 |
| Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Pharmacokinetic Study, Ulixertinib - Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2018-11-14 | 2026-09-21 |
| Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H) Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 35 | 2018-10-15 | 2026-11-05 |
| Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1) Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 35 | 2018-08-20 | 2026-09-15 |
| Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Locally Advanced, Metastatic, or Recurrent Cancer Dexamethasone, Exercise Intervention, Placebo Administration - Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid System Neoplasm | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 99 | 2018-06-29 | 2026-07-09 |
| Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F) Biopsy Procedure, Computed Tomography, Copanlisib Hydrochloride - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 35 | 2018-06-20 | 2026-11-05 |
| Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2018-06-05 | 2026-10-16 |
| Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 13 | 2018-04-17 | 2026-10-28 |
| Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A) Afatinib, Biopsy Procedure, Biospecimen Collection - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 19 | 2018-02-28 | 2026-07-17 |
| Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Recurrent Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 9 | 2017-08-23 | 2026-06-17 |
| Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E) Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 16 | 2017-08-21 | 2026-11-05 |
| Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies Avelumab, Ivuxolimab, Radiation Therapy - Advanced Malignant Solid Neoplasm, Castration-Resistant Prostate Carcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 173 | 2017-08-02 | 2026-10-23 |
Showing 20 of 51. Sign in to see all of them.
Lymphoma (32) · Multiple Myeloma (30) · Hematologic Neoplasms (18) · Neoplasm Metastasis (9) · Glioma (7) · Ependymoma (5) · Hepatoblastoma (5) · Histiocytosis, Langerhans-Cell (5) · Lymphoma, Non-Hodgkin (5) · Medulloblastoma (5) · Neuroblastoma (5) · Neuroectodermal Tumors, Primitive, Peripheral (5) · Rhabdoid Tumor (5) · Wilms Tumor (5) · Central Nervous System Neoplasms (4)
Neoplasms (51) · Neoplasms by Histologic Type (41) · Hemic and Lymphatic Diseases (37) · Immune System Diseases (37) · Immunoproliferative Disorders (37) · Lymphatic Diseases (37) · Lymphoproliferative Disorders (37) · Cardiovascular Diseases (31) · Hematologic Diseases (31) · Vascular Diseases (31) · Blood Protein Disorders (30) · Hemorrhagic Disorders (30) · Hemostatic Disorders (30) · Neoplasms, Plasma Cell (30) · Paraproteinemias (30)
Biopsy (24) · Specimen Handling (24) · Magnetic Resonance Spectroscopy (20) · X-Rays (10) · Nuclear Medicine Department, Hospital (9) · Crizotinib (5) · Phantoms, Imaging (5) · trametinib (5) · copanlisib (4) · erdafitinib (4) · larotrectinib (4) · palbociclib (4) · ulixertinib (4) · Afatinib (3) · GSK2636771 (3)
National Cancer Institute (NCI) (44) · M.D. Anderson Cancer Center (5) · Jonsson Comprehensive Cancer Center (1) · Roswell Park Cancer Institute (1)
United States (51) · Puerto Rico (6) · Canada (4) · Australia (2) · Guam (1)
David S Hong (3) · Filip Janku (3) · Sriram Yennu (3) · Aung Naing (2) · Jason J Luke (2) · John L Hays (2) · Kevin M Kalinsky (2) · Timothy A Yap (2) · Aaron S Mansfield (1) · Alain C Mita (1) · Alice Lee (1) · Alice T Shaw (1) · Amy S Clark (1) · Anne S Tsao (1) · David M Jackman (1)
PMID 31401903, PMID 26586415, PMID 31533818, PMID 32188704, PMID 32303619, PMID 32463741, PMID 32534809, PMID 33048619, PMID 33415580, PMID 33427689, PMID 33491277, PMID 33591402, PMID 33770291, PMID 34241781, PMID 34331589, PMID 34486544, PMID 34725215, PMID 35133871, PMID 35138919, PMID 35353553, PMID 35618285, PMID 35999229, PMID 36351402, PMID 37053535, PMID 37322121, PMID 37568622, PMID 37934000, PMID 38591867, PMID 38935895, PMID 39666929, PMID 39693587, PMID 39773433, PMID 39913886, PMID 40139261, PMID 40153687, PMID 40212844, PMID 40865033, PMID 41066729, PMID 41143139, PMID 41166674, PMID 41533998, PMID 41556942, PMID 41646361, PMID 42342409, PMID 42686334
U10CA180820 (33), U24CA196172 (18), U10CA180886 (5), UM1CA186688 (3), UM1CA186689 (3), P30CA016056 (1), R01CA164333 (1), R21NR016737 (1), UM1CA081457 (1), UM1CA186644 (1), UM1CA186705 (1), UM1CA186717 (1), ZIABC011078 (1)